Having withdrawn Blenrep (belantamab mafodotin-blmf) from the US market in 2022 after failing to confirm the benefit of the antibody-drug conjugate in late-line multiple myeloma, GSK plc is preparing to refile this year for use in the second-line setting based on the DREAMM-8 trial presented 2 June at the American Society of Clinical Oncology annual meeting. The company is confident that the DREAMM-7 and 8 trials together show a “consistency of treatment effect.”
ASCO: GSK Confident In DREAMM Of Returning Blenrep To Market
DREAMM-8 Trial Is Second Trial Supporting Second-Line Use
The antibody-drug conjugate, withdrawn from market for late-line use, is poised to make a return with strong results in DREAMM-7 and 8. GSK plans to refile later this year.
More from ASCO
• By
Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.
• By
The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers.
• By
Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.
• By
US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.